Transcatheter aortic valve implantation (TAVI) has matured into a standard treatment option
for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

The incidence of heart valve disease increases significantly with age. Degenerative
abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Objectives The purpose of this study was to examine the impact of residual mitral
regurgitation (MR) on mortality in patients undergoing transcatheter aortic valve replacement …

As transcatheter aortic valve replacement becomes a more dominant treatment option
across all risk profiles, the frequency of encountering patients with multivalvular disease will …

Objectives: The authors sought to investigate the prevalence, risk factors, and mid-term
mortality in Asian patients with prosthesis–patient mismatch (PPM) after transcatheter aortic …

Objectives The aim of this study was to describe baseline characteristics, and periprocedural
and mid-term outcomes of patients undergoing transcatheter mitral valve interventions post …

BACKGROUND Data on trends, predictors, and outcomes of heart failure (HF) readmissions
after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the …

Background Mixed valvular disease (MVD), mitral regurgitation (MR) from pre‐existing
disease in conjunction with paravalvular leak (PVL) following transcatheter aortic valve …